Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.380 +0.040 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,551,183
Open 7.450
Bid (Size) 7.370 (100)
Ask (Size) 7.410 (1,300)
Prev. Close 7.340
Today's Range 7.250 - 7.460
52wk Range 5.020 - 21.73
Shares Outstanding 98,983,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Via Investor Brand Network

Performance

YTD
-53.7%
-53.7%
1 Month
-36.5%
-36.5%
3 Month
-47.1%
-47.1%
6 Month
+2.8%
+2.8%
1 Year
+12.5%
+12.5%

More News

Read More
News headline image
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Mixed Q4 2025 Results, Highlights Extended Cash Runway to 2028 ↗
Via Chartmill
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Proposed Redomiciliation to the United States
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Is This Weight Loss Drug Stock a Buy on the Dip? ↗
Via The Motley Fool
News headline image
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗
Via The Motley Fool
Topics Stocks
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
Via MarketMinute
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences (WVE) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
News headline image
This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Wave Life Sciences Ltd. - Ordinary Shares publicly traded?
Yes, Wave Life Sciences Ltd. - Ordinary Shares is publicly traded.
What exchange does Wave Life Sciences Ltd. - Ordinary Shares trade on?
Wave Life Sciences Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares?
The ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares is WVE on the Nasdaq Stock Market
What is the current price of Wave Life Sciences Ltd. - Ordinary Shares?
The current price of Wave Life Sciences Ltd. - Ordinary Shares is 7.380
When was Wave Life Sciences Ltd. - Ordinary Shares last traded?
The last trade of Wave Life Sciences Ltd. - Ordinary Shares was at 04/22/26 04:00 PM ET
What is the market capitalization of Wave Life Sciences Ltd. - Ordinary Shares?
The market capitalization of Wave Life Sciences Ltd. - Ordinary Shares is 730.50M
How many shares of Wave Life Sciences Ltd. - Ordinary Shares are outstanding?
Wave Life Sciences Ltd. - Ordinary Shares has 730M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.